Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

HCP

- PMLiVE

Shire to focus rare disease R&D with new US facility

Cambridge, Massachusetts hub to drive firm’s push to become leading rare disease specialist

- PMLiVE

An exciting outlook for pre-approval access and compassionate use

How to deal with the ethical and practical considerations of the demand for promising new drugs that are in development

- PMLiVE

The new launch paradigm

The journey from capabilities excellence to effectiveness

Dispensing with the past

The pharma boards of the future

- PMLiVE

Orphan drugs: Leading the way in patient-centricity

What lessons about optimal patient engagement can big pharma learn from those operating in rare disease?

- PMLiVE

UK to cut wait to innovative treatments by four years

Proposals in the Accelerated Access Review aim to speed up access to innovation

- PMLiVE

Access to orphan drugs for rare cancers in EU28

Although the economic burden imposed by rare cancers has not yet been adequately assessed, the treatment burden posed by rare cancers on individuals, societies and healthcare systems make them a...

Access to orphan drugs for rare cancers in EU28

Although the economic burden imposed by rare cancers has not yet been adequately assessed, the treatment burden posed by rare cancers on individuals, societies and healthcare systems make them a...

- PMLiVE

Pharma ‘could do better’ on social media engagement

Industry is comfortable with the tech but has work to do on its approach

- PMLiVE

Roche creates the Fight IPF choir for disease awareness campaign

Aims to raise the lung disease's profile and inform patients and their families

- PMLiVE

Time for a new language for asthma?

Many patients lack an understanding of what ‘control’ means

Celgene building

Celgene plans real-world study using Apple’s ResearchKit

Will develop an iPhone app to assess burden of chronic anaemia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links